Mayinglong Pharmaceutical Group Co Ltd (600993) — Capital Reinvestment Ratio
Mayinglong Pharmaceutical Group Co Ltd (600993) has a Capital Reinvestment Ratio of 0.10x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥139.20 Million) in capital expenditures (CN¥13.73 Million). See how leveraged is Mayinglong Pharmaceutical Group Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Mayinglong Pharmaceutical Group Co Ltd Capital Reinvestment Ratio (2003–2025)
This chart tracks Mayinglong Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 22 annual periods. Check cash flow reinvestment rate of Mayinglong Pharmaceutical Group Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Mayinglong Pharmaceutical Group Co Ltd (2003–2025)
Year-by-year Capital Reinvestment Ratio for Mayinglong Pharmaceutical Group Co Ltd from 2003 to 2025. For live market cap and broader valuation context, see Mayinglong Pharmaceutical Group Co Ltd (600993) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | CN¥600.44 Million | CN¥119.37 Million | ▼ -51.5% |
| 2024 | 0.41x | CN¥497.61 Million | CN¥203.85 Million | ▼ -0.4% |
| 2023 | 0.41x | CN¥604.07 Million | CN¥248.36 Million | ▲ +87.4% |
| 2022 | 0.22x | CN¥341.85 Million | CN¥75.01 Million | ▲ +101.3% |
| 2021 | 0.11x | CN¥597.17 Million | CN¥65.10 Million | ▼ -32.1% |
| 2020 | 0.16x | CN¥282.99 Million | CN¥45.41 Million | ▲ +70.2% |
| 2019 | 0.09x | CN¥491.58 Million | CN¥46.36 Million | ▲ +16.4% |
| 2018 | 0.08x | CN¥308.24 Million | CN¥24.96 Million | ▼ -31.2% |
| 2017 | 0.12x | CN¥356.17 Million | CN¥41.91 Million | ▼ -56.8% |
| 2016 | 0.27x | CN¥239.60 Million | CN¥65.24 Million | ▼ -59.8% |
| 2015 | 0.68x | CN¥182.85 Million | CN¥123.93 Million | ▼ -29.2% |
| 2014 | 0.96x | CN¥111.67 Million | CN¥106.87 Million | ▲ +48.6% |
| 2013 | 0.64x | CN¥129.94 Million | CN¥83.68 Million | ▲ +232.8% |
| 2012 | 0.19x | CN¥169.25 Million | CN¥32.75 Million | ▼ -67.4% |
| 2011 | 0.59x | CN¥75.37 Million | CN¥44.69 Million | ▲ +266.9% |
| 2009 | 0.16x | CN¥216.11 Million | CN¥34.93 Million | ▼ -49.5% |
| 2008 | 0.32x | CN¥102.59 Million | CN¥32.84 Million | ▼ -91.6% |
| 2007 | 3.80x | CN¥6.49 Million | CN¥24.65 Million | ▲ +1242.0% |
| 2006 | 0.28x | CN¥75.27 Million | CN¥21.32 Million | ▼ -54.0% |
| 2005 | 0.62x | CN¥58.43 Million | CN¥35.95 Million | ▲ +15.2% |
| 2004 | 0.53x | CN¥54.19 Million | CN¥28.94 Million | ▲ +148.1% |
| 2003 | 0.22x | CN¥67.52 Million | CN¥14.54 Million | — |